drug
(halobetasol propionate + tazarotene)
Marketedupdated 3mo agoby Ortho Dermatologics Inc
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying (halobetasol propionate + tazarotene)
Patent cliff
source: FDA Orange Bookfirst barrier falls
Nov 2, 2031
~5.2 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (10)
- Jun 6, 2036formulationUS 10251895
- Jun 6, 2036method-of-use (U-2625)US 10426787
- Jun 6, 2036formulationUS 11648256
- Jun 6, 2036formulationUS 11679115
- Nov 2, 2031formulationUS 10478502
- Nov 2, 2031method-of-use (U-2625)US 11839656
- Nov 2, 2031formulationUS 11957753
- Nov 2, 2031method-of-use (U-2625)US 11986527
- Nov 2, 2031formulationUS 12076403
- Nov 2, 2031formulationUS 8809307
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that